øisentia

AUTHOR: Bernama MARKET: Malaysia

PHOTO: Full Color ASR: MYR 5,400.00

SECTION: HOME PAGE: 1,4 PRINTED SIZE: 396.00cm² REGION: KL ITEM ID: MY0045841600



02 NOV, 2021

PM launches National Vaccine Devt Roadmap



Borneo Post (Kuching), Malaysia

Page 1 of 3

PM launches National Vaccine Devt Roadmap

BANGI: Prime Minister Datuk Seri Ismail Sabri Yaakob yesterday launched the National Vaccine Development Roadmap (PPVN) and Malaysian Genome and Vaccine Institute (MGVI) in an effort to turn the country into a hub for vaccine production and boost confidence in vaccine use.

He said through PPVN and MGVI, Malaysia could produce its own vaccines that are of quality, effective and safe in accordance with the conditions set by the National Pharmaceutical

Regulatory Agency (NPRA). "Although R&D and vaccine production require heavy investment, such efforts have the potential to bring long-term returns for Keluarga Malaysia (Malaysian Family) in the form of cost savings in treating diseases and investments by multinational companies in Malaysia.

"Through the implementation of PPVN and establishment of MGVI, highly skilled human capital in various fields of research especially those related to healthcare and vaccines can be produced," he said at the launch at the ceremony Malaysian Genome Institute (MGI) here.

Also present were Science, Technology and Innovation Minister Datuk Seri Dr Adham Baba and Health Minister Khairy Jamaluddin. "More job opportunities can be created for Keluarga Malaysia to help increase the number of skilled and workers enhance the standard of living and health of the people," he added.

Ismail Sabri said PPVN would not be focusing solely on Covid-19 and its role would be expanded to include development of vaccines for other diseases, including head and neck cancer by the Cancer Research Centre.

He said three projects are ready be implemented through PPVN, with the first involving the production of two types of Covid-19 using inactivated virus and mRNA developed by the Institute for Medical Research (IMR). He said for this purpose, the

fund extended by the government involved research allocations to the Health Ministry (MOH) and Sukuk Prihatin (Covid-19 research allocation special aid) totalling RM3.5 million.

The second project, entitled evelopment of Mucosal/ Development Oral/Subunit Vaccines Against Tuberculosis Cholera. and Covid-19, is on cholera vaccine developed in collaboration with Universiti Sains Malaysia (USM) and Asian Institute of Medicine, Science and Technology (AIMST), with the Ministry of Science, Technology and Innovation Technology and Innovation (Mosti) also funding it to the tune of RM10.5 million using the Strategic Research Fund (SRF), he said.

> Turn to Page 4, Col 4

Provided for client's internal research purposes only. May not be further copied, distributed, sold or published in any form without the prior consent of the copyright owner.

øisentia

AUTHOR: Bernama

MARKET: Malaysia PHOTO: Full Color ASR: MYR 5,400.00

SECTION: HOME PAGE: 1,4 PRINTED SIZE: 396.00cm² REGION: KL ITEM ID: MY0045841600



02 NOV, 2021

PM launches National Vaccine Devt Roadmap



Borneo Post (Kuching), Malaysia

Page 2 of 3

CRM to run cancer clinical trial from 2022 to 2023 in UK

>From Page 1

"The third project is on Pre-clinical Evaluation of a Therapeutic Cancer Vaccine for the Treatment of Head and Neck Cancer by Cancer Research Malaysia (CRM) at a cost of RM3 million financed by Mosti. "However, as there is no facility

yet to conduct the first in human clinical trial in Malaysia, CRM will conduct the clinical trial from February 2022 until March 2023 in the United Kingdom," he said.

On MGVI, he said upgrading IGI was in line with the MGI institute's scope, which focused on genome research and molecular biology in vaccine

"I am confident that the establishment of MGVI can have a positive impact on the country from the economic, social and technological aspects; thus contributing to economic stability because there is no dependence on external sources

of supply," he said. Ismail Sabri said the government was committed to propelling R&D to produce new technologies by ensuring that 50 per cent of the government's research funds were provided for experimental development (pre -commercialisation activities), especially for innovations with high potential for

commercialisation. Through various programmes implemented by the government, he said, the country expected more vaccine scientists to be produced; thus supporting its plan to increase the ability to develop human-specific vaccines, not only for domestic use but also the global market.


He also expressed confidence that Malaysia could reduce its dependence on vaccineproducing countries when it strengthened the country's health security. — Bernama



Ismail Sabri (right) stops by at an exhibition booth after the launch of the PPVN and the MGVI. Bernama photo

	THE NATIONAL VACCINE DEVELOPMENT ROADMAP (PPVN) Was issuected on New 1, 2021			on ring infrastructure	
			Clinical s		
2 Will be	implemented by MOSTI &			apital development	
3 Focuss vaccine	ed on more than the COV			gy acquisition on communication	
4 Interest various	ted in vaccine developme diseases including cance	ent for	PROD	UCTION PHASES	
head &	neck	es or the		erm (quick win solution): Vears	5 - 10 years
HE MALAYSIAN GENOME		MGVI OBJECTIVES	00151745		
ACCINE INSTITUTE (MGV Earlier known as the Malay	sian of phan	 To reduce dependence on the importation of pharmaceuticals To build human capital highly skilled in research, especially in the fields of; 		 To attract investment from multinational corporations 	
Genome Institute (MGI) beh upgraded on Oct 29, 2021	one it was To build			To produce vaccines determined by the Nation Pharmaceutical Regulatory Agency (NPRA) as:	
Will provide research facilities	2	😹 Health		Sale	
for vaccine development	S	Vaccines Vaccines		Effective	
0	 To creat 	To create employment		VI quality	
an is		. To improve the quality of life		+ To prepare for future pandemics	
and a	• To prov	To provide a return on investment		 To contribute to the biotechnology sector, bioeconomy & human capital development 	
		PPVN PRO	JECT	S	>
1	mmiller	minum	ilii.	unul	
2 types of veccines	(2 ch	2 Chokera vaccine		3 Preclinical Evaluation of a Therapoutic Cancer Vaccine for the Treatment of Head & Neck Cancer	
. An inactivated & mRNA	ectivated & mRNA +Being developed by USM & AIMST developed by the Institute for al Research, Malaysia (MR) +Provided RM10.5 million by MOSTI		T		
 Being developed by the le Medical Research, Malavi 			n	By Cancer Research Malaysia (CRM)	
.Focussed on fighting loca	10.00 C			 Provided RM3 million by MOSTI Clinical trial to be conducted in the United 	
of concern (VOC) • Provided RM3.5 million by Sukuk Prihatin	y MOH &			Kingdom from Februar	
0570 Ministry of Science, Technolog OH, Ministry of Neutlin, Malaesia	y & Innovation, Malaysia	will Messenger Abonucleic at USM: Université Yales, Malopsia	н	AMS7. Asian Institute of Medic	ine. Science & Technology
	and the second se	bri Yaakob/			Published: Nov 1, 20

Provided for client's internal research purposes only. May not be further copied, distributed, sold or published in any form without the prior consent of the copyright owner.



SUMMARIES

BANGI: Prime Minister Datuk Seri Ismail Sabri Yaakob yesterday launched t h e National Vaccine Development Roadmap (PPVN) and Malaysian Genome and Vaccine I n s t i t u t e (MGVI) in an e f f o r t t o t u r n t h e country into a hub for vaccine production and boost confidence in vaccine use.